Italia markets close in 9 minutes
FTSE MIB
35.390,18 -19,95 (-0,06%) Dow Jones
39.900,68 +31,30 (+0,08%) Nasdaq
16.704,94 +6,62 (+0,04%) Nikkei 225
38.787,38 -132,88 (-0,34%) Petrolio
79,38 +0,15 (+0,19%) Bitcoin EUR
61.618,16 +1.163,05 (+1,92%)
NBIX May 2024 140.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 10:36AM EDT. Mercato aperto.
| Chiusura precedente | 0,4400 |
| Aperto | 0,4500 |
| Denaro | 0,0000 |
| Lettera | 1,8000 |
| Prezzo d'esercizio | 140,00 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 0,4500 - 0,4500 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 38 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.